Led to a reduction of serum cholesterol of around 80 percent.

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study – Gene Therapy Vector Successfully Delivers shRNA Into Liver Cells Amsterdam Molecular Therapeutics a global leader in gene therapy, today reported positive preclinical data from a scholarly research using an AAV gene therapy product to lower cholesterol. The data show a single dosage of the gene therapy having a short hairpin RNA to silence Apolipoprotein B100 , led to a reduction of serum cholesterol of around 80 percent, without any signs of toxicity. These data validate AMT’s technology system as a robust tool for effective gene silencing within focus on cells her .